Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:05 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis
NCT04396366 · Novartis Pharmaceuticals · PHASE2 · terminated · last registry update 2025-09-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Strategic business decision” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CFTR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-03-10Results posted on the registry: Beth Israel Deaconess Medical Center, Crofelemer + Placebo (NCT04486326)
- 2026-03-10Also stopped (terminated): Beth Israel Deaconess Medical Center, Crofelemer + Placebo (NCT04486326)
- 2026-02-12Results posted on the registry: The University of Texas Health Science Center, Houston, Crofelemer (NCT03898856)
- 2025-09-11Results posted on the registry: Emory University, Trikafta (NCT03506061)
- 2025-05-18Results posted on the registry: Vertex Pharmaceuticals Incorporated, ELX/TEZ/IVA + IVA (NCT04183790)
- 2025-04-16Results posted on the registry: University of Alabama at Birmingham, Symdeko + Ivacaftor and Symdeko (NCT03624101)
- 2025-04-16Also stopped (terminated): University of Alabama at Birmingham, Symdeko + Ivacaftor and Symdeko (NCT03624101)
- 2024-12-06Phase 3 first posted: Napo Pharmaceuticals, Inc., Crofelemer Powder for Oral Solution + Placebo Powder for Oral Solution (NCT06721871)
- 2024-10-23Results posted on the registry: Vertex Pharmaceuticals Incorporated, IVA (NCT03277196)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision